Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mei-Chyn Chao is active.

Publication


Featured researches published by Mei-Chyn Chao.


Human Genetics | 1998

Identification of four novel mutations in the CYP21 gene in congenital adrenal hyperplasia in the Chinese

Hsien-Hsiung Lee; Hsiang-Tai Chao; Yann-Jinn Lee; San-Ging Shu; Mei-Chyn Chao; Jing-Mei Kuo; Bun-chu Chung

Abstract Congenital adrenal hyperplasia (CAH) is a common autosomal recessive disorder mainly caused by defects in the steroid 21-hydroxylase (CYP21) gene. We have analyzed CYP21 gene sequences in 65 CAH families in Taiwan. All ten exons of the CYP21 gene were analyzed by differential polymerase chain reaction followed by single-strand conformation polymorphism electrophoresis and the amplification-created restriction site method. About 95% (123 chromosomes) contain mutations due to conversion of DNA sequences into its neighboring homologous pseudogene, CYP21P. Four novel mutations representing 5% of the total chromosomes have also been identified. The mutations were confirmed by sequencing an aberrant DNA fragment. These four mutations included a base change of the splicing donor site at intron 2 from GT to AT, a base substitution of C to T at codon 316, deletion of ten bases (TCCAGCTCCC) at codons 330–333 of exon 8, and duplication of 16 bases (CCTGGATGACACGGTC) at codons 393–397 of exon 9. The loss of the splicing donor site at intron 2 and the premature stop at codon 316 may result in aberrant splicing to reduce enzyme activity and a truncated protein with no enzyme activity, respectively. Likewise, both the duplication and the deletion forms create a frameshift and premature stop during translation. The resulting proteins lack the heme-binding domain and hence are expected to lose enzymatic activity. Since these mutations are not found in the neighboring CYP21P pseudogene, gene conversion should not be the cause of these novel mutations.


American Journal of Medical Genetics Part A | 2005

Prevalence of the FMR1 mutation in Taiwan assessed by large‐scale screening of newborn boys and analysis of DXS548‐FRAXAC1 haplotype

Ching-Cherng Tzeng; Li-Ping Tsai; Wuh-Liang Hwu; Shio-Jean Lin; Mei-Chyn Chao; Yuh-Jyh Jong; Shao-Yin Chu; Wei-Chen Chao; Chin-Li Lu

If carrier women could be identified in time and take appropriate measures, fragile X syndrome (FXS) can be prevented. Wide screening of women to be or in their early pregnancy was considered a good approach to identify carriers without misdetection. Nevertheless, we argued against the cost‐effectiveness of implementing such a screening program in Taiwan, due to the lower carrier rate found in our pilot study. To reliably estimate the prevalence of mutant FMR1 gene in Taiwan, we anonymously screened 10,046 newborn boys using bloodspot polymerase chain reaction (PCR). Among them, the sample from one boy, who was most likely had FXS, failed repeatedly in PCR amplification. The estimated prevalence of premutation (55–200 CGG repeats) and intermediate alleles (45–54 CGG repeats) was 1:1,674 (n = 6) and 1:143 (n = 70), respectively. All these estimates were constantly lower than that reported in Caucasian populations, with variable statistic significance. Furthermore, when comparing analyses of the distribution of alleles at the two most often investigated microsatellite loci, DXS548 and FRAXAC1, between 100 control and 28 unrelated fragile X chromosomes, we found no apparent founder haplotype prevalent among the fragile X patients. Because a few founder haplotypes were reportedly prevalent in two thirds of fragile X alleles in Caucasians and in Chinese from Central China, we thus suggested that lack of founder fragile X chromosomes might result in a relatively low prevalence of mutant FMR1 gene in a population, as observed in Taiwan.


Acta Paediatrica | 2007

Genotype and phenotype in patients with Prader–Willi Syndrome in Taiwan

Hsiang-Yu Lin; Shuan-Pei Lin; Chih-Kuang Chuang; Ming-Ren Chen; Jui-Lung Yen; Yann-Jinn Lee; Chi-Yu Huang; Li-Ping Tsai; Dau-Ming Niu; Mei-Chyn Chao; Pao-Lin Kuo

Aim: Several different genetic defects have been found to result in the characteristic phenotypic expression of Prader–Willi syndrome (PWS).


European Journal of Pediatrics | 2009

Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature

Ju-Li Lin; Min-Tzu Kuo; Pao-Chin Chiu; San-Ging Shu; Mei-Chyn Chao; Yann-Jinn Lee; Shuan-Pei Lin

Noonan syndrome is a highly variable disorder that has significant phenotypic overlap with Costello syndrome and cardio-facio-cutaneous syndrome. KRAS mutation was the second reported gene for Noonan syndrome. This study screened for mutation of the KRAS gene in 57 unrelated ethnic Chinese children suffering from Noonan syndrome without PTPN11 gene mutation in Taiwan. This work only identified two patients with different missense mutations (c.40G>A, p.Val14Ile; c.108A>G, p.Ile36Met) in the exon 1 of KRAS gene. This study also analyzed the characteristics of 34 reported cases involving KRAS mutations in the literature. All these patients presented with variable phenotypes, including Noonan syndrome (n = 19), cardio-facio-cutaneous syndrome (n = 7), Costello syndrome (n = 6), and Noonan/cardio-facio-cutaneous syndrome (n = 1). The phenotype of KRAS mutations was generally severe, including short stature, mental retardation, heart defects, etc. In conclusion, this investigation demonstrates that KRAS mutations are the cause in a minority of cases of Chinese patients with Noonan syndrome in Taiwan.


European Neurology | 2004

DNA Haplotype Analysis of CAG Repeat in Taiwanese Huntington’s Disease Patients

C.K. Wang; Yih-Ru Wu; Wuh-Liang Hwu; C.M. Chen; Long-Sun Ro; Sien-Tsong Chen; Katrina Gwinn-Hardy; Chih-Chao Yang; Ruey-Meei Wu; Ta-Fu Chen; Hung-Ming Wang; Mei-Chyn Chao; Ming-Jang Chiu; C.J. Lu; Guey-Jen Lee-Chen

We studied the expanded CAG repeat and adjacent CCG repeat in 53 Huntington’s disease (HD) patients and 172 unrelated normal subjects matched to the patients for ethnic origin. The range of the CAG repeat varied from 38 to 109 in the HD patients and from 10 to 29 in the control group. A significant negative correlation was found between the age at onset and the CAG expansion, with no significant influence of the adjacent CCG repeat on the age at onset by multiple regression analysis. Allelic association using CCG repeat and 2 flanking dinucleotide repeat markers within 150 kb of the HD gene revealed linkage disequilibrium for 2 of 3 markers. Haplotype analysis of 24 HD families using these markers identified 3 major haplotypes underlying 87.5% of HD chromosomes. The data suggested frequent haplotypes in the Taiwanese population on which one or more mutational events leading to the disease occurred.


Journal of The Formosan Medical Association | 2007

Mutational Analysis of PTPN11 Gene in Taiwanese Children with Noonan Syndrome

Chia-Sui Hung; Ju-Li Lin; Yann-Jinn Lee; Shuan-Pei Lin; Mei-Chyn Chao

Noonan syndrome (NS) is an autosomal dominant disorder presenting with characteristic facies, short stature, skeletal anomalies, and congenital heart defects. Mutations in protein-tyrosine phosphatase, nonreceptor-type 11 (PTPN11), encoding SHP-2, account for 33-50% of NS. This study screened for mutations in the PTPN11 gene in 34 Taiwanese patients with NS. Mutation analysis of the 15 coding exons and exon/intron boundaries was performed by polymerase chain reaction and direct sequencing of the PTPN11 gene. We identified 10 different missense mutations in 13 (38%) patients, including a novel missense mutation (855T>G, F285L). These mutations were clustered in exon 3 (n = 6) encoding the N-SH2 domain, exon 4 (n = 2) encoding the C-SH2 domain, and in exons 8 (n = 2) and 13 (n = 3) encoding the PTP domain. In conclusion, this study provides further support that PTPN11 mutations are responsible for Noonan syndrome in Taiwanese patients.


Journal of The Chinese Medical Association | 2008

Effects of Growth Hormone Treatment on Height, Weight, and Obesity in Taiwanese Patients with Prader-Willi Syndrome

Hsiang-Yu Lin; Shuan-Pei Lin; Li-Ping Tsai; Mei-Chyn Chao; Ming-Ren Chen; Chih-Kuang Chuang; Chi-Yu Huang; Fuu Jen Tsai; I-Ching Chou; Pao-Ching Chiu; Cheng-Hung Huang; Jui-Lung Yen; Ju-Li Lin; Pao-Lin Kuo

Background: Information regarding the efficacy of growth hormone (GH) therapy in Asian Prader‐Willi syndrome (PWS) patients is lacking. We report our experience with GH treatment in children with PWS in Taiwan. Methods: Forty‐six PWS patients (27 males, 19 females; age range, 1 year 4 months to 13 years 7 months) who received and/or who are currently receiving GH treatment (0.1 IU/kg/day subcutaneously) for a period from 1 year to 3 years were retro‐spectively analyzed. We evaluated height, weight, body mass index (BMI) and Rohrer index, before and after GH treatment. Results: After patients had received GH for 1, 2 and 3 years, a significant improvement in mean height standard deviation score (SDS) was noted from −1.24 to −0.31 (p <0.01), 0.00 (p <0.001) and −0.26 (p <0.001), respectively. Mean BMI SDS decreased significantly from 1.93 to 1.13 (p <0.05) after 1 year of treatment; however, no significant changes were observed afterward. Mean Rohrer index decreased significantly, from 224.2 to 186.6 (p <0.001), 178.9 (p <0.001) and 169.3 (p <0.001). No significant gender or genotype pattern differences were noted among the 4 parameters examined. Conclusion: This 3‐year, retrospective study indicates that PWS patients benefit from GH therapy in height increase and improved body composition.


Pediatrics International | 2007

Prader-Willi syndrome in Taiwan

Hsiang-Yu Lin; Shuan-Pei Lin; Jui-Lung Yen; Yann-Jinn Lee; Chi-Yu Huang; Han-Yang Hung; Chyong-Hsin Hsu; Hsin-An Kao; Jui‐Hsing Chang; Nan-Chang Chiu; Che-Sheng Ho; Mei-Chyn Chao; Dau-Ming Niu; Li-Ping Tsai; Pao-Lin Kuo

Background: Prader–Willi syndrome (PWS) is a congenital disorder caused by absent expression of paternal genes in 15q11‐13 affecting multiple systems. The information concerning the clinical features of this genetic disorder is incomplete in Taiwan.


JIMD reports | 2013

Fatty Acid oxidation disorders in a chinese population in taiwan.

Yin-Hsiu Chien; Ni-Chung Lee; Mei-Chyn Chao; Li-Chu Chen; Li-Hsin Chen; Chun-Ching Chien; Hui-Chen Ho; Jeng-Hung Suen; Wuh-Liang Hwu

BACKGROUND Fatty acid oxidation (FAO) disorders are a heterogeneous group of inborn errors in the transportation and oxidation of fatty acids. FAO disorders were thought to be very rare in the Chinese population. Newborn screening for FAO disorders beginning in 2002 in Taiwan may have increased the diagnosis of this group of diseases. MATERIALS AND METHODS Till 2012, the National Taiwan University Hospital Newborn Screening Center screened more than 800,000 newborns for FAO disorders. Both patients diagnosed through screening and patients detected after clinical manifestations were included in this study. RESULTS A total of 48 patients with FAO disorders were identified during the study period. The disorders included carnitine palmitoyltransferase I deficiency, carnitine acylcarnitine translocase deficiency, carnitine palmitoyltransferase II deficiency, very long-chain acyl-CoA dehydrogenase deficiency, medium-chain acyl-CoA dehydrogenase deficiency, multiple acyl-CoA dehydrogenase deficiency, short-chain defects, and carnitine uptake defect. Thirty-nine patients were diagnosed through newborn screening. Five false-negative newborn screening cases were noted during this period, and four patients who were not screened were diagnosed based on clinical manifestations. The ages of all patients ranged from 6 months to 22.9 years (mean age 6.6 years). Except for one case of postmortem diagnosis, there were no other mortalities. CONCLUSIONS The combined incidence of FAO disorders estimated by newborn screening in the Chinese population in Taiwan is 1 in 20,271 live births. Newborn screening also increases the awareness of FAO disorders and triggers clinical diagnoses of these diseases.


Journal of The Formosan Medical Association | 2006

Novel SOX9 Gene Mutation in Campomelic Dysplasia with Autosomal Sex Reversal

Hui-Pin Hsiao; Li-Ping Tsai; Mei-Chyn Chao; Hsin-I Tseng; Yuli C. Chang

Campomelic dysplasia (CD; OMIM #114290) is an autosomal dominant, frequently lethal dysplasia syndrome whose primary features include angular bowing and shortening of the limbs, and sex reversal in the majority of affected XY individuals. Most CD cases have heterozygous de novo mutations in the coding region of the transcription factor gene SOX9 (SRY-related high-mobility group [HMG] box 9) in chromosome 17q. Here, we report a novel mutation of SOX9 in a female neonate with CD with autosomal sex reversal. Respiratory distress and cyanosis were noted at birth, and endotracheal intubation with mechanical ventilation was performed due to respiratory failure. The presenting phenotypes included dysmorphic face with macrocephaly, prominent forehead, low nasal bridge, cleft palate and micrognathia. Skeletal deformities characteristic of CD were observed, including narrow thoracic cage, hypoplastic scapulae, scoliosis and short limbs with anterolateral femoral and tibial bowing. The karyotype was 46,XY despite female external genitalia. SOX9 gene analysis revealed frameshift mutation (at nucleotide position 1095G-->AT) in the open reading frame, resulting in a frameshift with 211 new amino acids.

Collaboration


Dive into the Mei-Chyn Chao's collaboration.

Top Co-Authors

Avatar

Yann-Jinn Lee

Mackay Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Shuan-Pei Lin

Mackay Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Li-Ping Tsai

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Chi-Yu Huang

Mackay Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Hui-Pin Hsiao

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Wuh-Liang Hwu

National Taiwan University

View shared research outputs
Top Co-Authors

Avatar

Ju-Li Lin

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Dau-Ming Niu

Taipei Veterans General Hospital

View shared research outputs
Top Co-Authors

Avatar

Hsiang-Yu Lin

Mackay Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Jui-Lung Yen

Kaohsiung Medical University Chung-Ho Memorial Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge